SK bioscience Co.,Ltd. (KRX:302440)
South Korea · Delayed Price · Currency is KRW 41,000
-1,300 (-3.07%)
At close: May 27, 2026
SK bioscience Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 665,421 | 651,368 | 267,545 | 369,506 | 456,726 | 929,001 |
Other Revenue | - | -0 | - | - | -0 | - |
| 665,421 | 651,368 | 267,545 | 369,506 | 456,726 | 929,001 | |
Revenue Growth (YoY) | 66.42% | 143.46% | -27.59% | -19.10% | -50.84% | - |
Cost of Revenue | 601,627 | 576,192 | 237,466 | 227,681 | 217,443 | 358,968 |
Gross Profit | 63,795 | 75,177 | 30,079 | 141,824 | 239,283 | 570,033 |
Selling, General & Admin | 117,876 | 110,993 | 87,056 | 60,841 | 61,801 | 46,027 |
Research & Development | 78,847 | 69,861 | 71,353 | 85,743 | 57,960 | 47,250 |
Amortization of Goodwill & Intangibles | 11,901 | 10,809 | 4,220 | 1,938 | 963.13 | 680.01 |
Other Operating Expenses | 1,525 | 1,411 | 1,274 | 1,417 | 664.99 | 388.56 |
Operating Expenses | 216,705 | 198,678 | 168,511 | 153,812 | 124,269 | 95,813 |
Operating Income | -152,911 | -123,502 | -138,431 | -11,988 | 115,014 | 474,220 |
Interest Expense | -10,710 | -9,399 | -3,685 | -1,398 | -2,461 | -3,427 |
Interest & Investment Income | 17,576 | 15,674 | 6,978 | 13,555 | 4,854 | 1,517 |
Currency Exchange Gain (Loss) | -10,186 | -13,012 | 3,137 | 13,325 | 16,506 | -1,662 |
Other Non Operating Income (Expenses) | 1,334 | 2,955 | 4,474 | -18,722 | -28,620 | -434.77 |
EBT Excluding Unusual Items | -154,897 | -127,284 | -127,527 | -5,228 | 105,293 | 470,212 |
Gain (Loss) on Sale of Investments | 4,010 | 10,444 | 24,162 | 13,777 | 36,875 | 892.14 |
Gain (Loss) on Sale of Assets | 30,983 | 30,979 | 14,259 | -68.06 | -434.6 | 23.62 |
Asset Writedown | - | - | -1.41 | -1,154 | - | - |
Pretax Income | -119,904 | -85,860 | -89,107 | 7,327 | 141,733 | 471,128 |
Income Tax Expense | -31,638 | -29,687 | -38,990 | -14,990 | 19,281 | 115,989 |
Earnings From Continuing Operations | -88,266 | -56,173 | -50,117 | 22,318 | 122,452 | 355,139 |
Minority Interest in Earnings | 4,980 | -1,251 | -3,764 | - | - | - |
Net Income | -83,286 | -57,424 | -53,881 | 22,318 | 122,452 | 355,139 |
Net Income to Common | -83,286 | -57,424 | -53,881 | 22,318 | 122,452 | 355,139 |
Net Income Growth | - | - | - | -81.77% | -65.52% | - |
Shares Outstanding (Basic) | 78 | 78 | 77 | 77 | 77 | 73 |
Shares Outstanding (Diluted) | 78 | 78 | 77 | 77 | 77 | 74 |
Shares Change (YoY) | 0.80% | 1.51% | 0.24% | -0.01% | 4.32% | - |
EPS (Basic) | -1063.36 | -732.77 | -697.93 | 290.65 | 1596.18 | 4844.07 |
EPS (Diluted) | -1063.58 | -733.00 | -698.00 | 290.00 | 1590.00 | 4810.00 |
EPS Growth | - | - | - | -81.76% | -66.94% | - |
Free Cash Flow | -179,846 | -80,584 | -292,433 | -14,114 | -197,951 | 493,686 |
Free Cash Flow Per Share | -2296.19 | -1028.30 | -3787.93 | -183.27 | -2570.08 | 6686.61 |
Gross Margin | 9.59% | 11.54% | 11.24% | 38.38% | 52.39% | 61.36% |
Operating Margin | -22.98% | -18.96% | -51.74% | -3.24% | 25.18% | 51.05% |
Profit Margin | -12.52% | -8.82% | -20.14% | 6.04% | 26.81% | 38.23% |
Free Cash Flow Margin | -27.03% | -12.37% | -109.30% | -3.82% | -43.34% | 53.14% |
EBITDA | -57,636 | -32,486 | -89,206 | 22,777 | 142,250 | 492,995 |
EBITDA Margin | -8.66% | -4.99% | -33.34% | 6.16% | 31.15% | 53.07% |
D&A For EBITDA | 95,275 | 91,016 | 49,225 | 34,765 | 27,236 | 18,775 |
EBIT | -152,911 | -123,502 | -138,431 | -11,988 | 115,014 | 474,220 |
EBIT Margin | -22.98% | -18.96% | -51.74% | -3.24% | 25.18% | 51.05% |
Effective Tax Rate | - | - | - | - | 13.60% | 24.62% |
Advertising Expenses | - | 3,432 | 2,296 | 1,849 | 1,190 | 1,909 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.